Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma

NCT01478178 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioma
Glioblastoma
Glioblastoma Multiforme
GBM
Brain Cancer

Interventions

DRUG: VAL-083 (Dianhydrogalactitol)

Sponsor

Kintara Therapeutics, Inc.